Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 330Breast Neoplasms 185Lung Neoplasms 177Ovarian Neoplasms 156Triple Negative Breast Neoplasms 88Fallopian Tube Neoplasms 75Squamous Cell Carcinoma of Head and Neck 74Small Cell Lung Carcinoma 67Esophageal Neoplasms 55Neoplasms 49Head and Neck Neoplasms 47Carcinoma, Ovarian Epithelial 44Uterine Cervical Neoplasms 36Esophageal Squamous Cell Carcinoma 36Endometrial Neoplasms 35Prostatic Neoplasms 33Neoplasm Metastasis 32Lymphoma, Large B-Cell, Diffuse 32Recurrence 31Adenocarcinoma of Lung 31Lymphoma 30Brain Neoplasms 29Neuroblastoma 24Central Nervous System Neoplasms 24Retinoblastoma 23Lymphoma, Non-Hodgkin 23Carcinoma, Squamous Cell 23Hodgkin Disease 20Testicular Neoplasms 19Urinary Bladder Neoplasms 16

Interventions

pembrolizumab 1Taxes 1Panitumumab 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Erythema × Carboplatin × Clear all
NCT02876107 2026-04-15

Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
42 enrolled
Breast

Breast Neoplasms, Edema, Erythema, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡